In particular, in a cohort of 105 patients with RET fusion-positive advanced NSCLC who had previously received platinum-based first-line chemotherapy, a response rate of 64% (95% CI: 54, 73%) was reported with the FDA approval of, selpercatinib, while a response rate of 85% (95% CI: 70%, 94%) was reported for treatment naive patients with RET-fusion positive advanced NSCLC treated with selpercatinib (6). The gene discussed is RET; the disease is non-small cell lung carcinoma.